HDAC9 and neoplasm: Moreover, epigenetic agents such as HDAC inhibitors show robust activation of interferon signaling in models, yet their clinical efficacy may be attenuated by epigenetic heterogeneity and intrinsic tumor resistance in patients [186,187].